Your browser doesn't support javascript.
loading
Adverse Events of Immune Checkpoint Inhibitors Therapy for Urologic Cancer Patients in Clinical Trials: A Collaborative Systematic Review and Meta-analysis.
Wu, Zhenjie; Chen, Qi; Qu, Le; Li, Mingmin; Wang, Linhui; Mir, Maria C; Carbonara, Umberto; Pandolfo, Savio D; Black, Peter C; Paul, Asit K; Di Lorenzo, Giuseppe; Porpiglia, Francesco; Mari, Andrea; Necchi, Andrea; Rouprêt, Morgan; Psutka, Sarah P; Autorino, Riccardo.
Afiliación
  • Wu Z; Department of Urology, Changhai Hospital, Naval Medical University, Shanghai, China.
  • Chen Q; Department of Health Statistics, Naval Medical University, Shanghai, China.
  • Qu L; Department of Urology, Jinling Hospital, Clinical School of Medical College, Nanjing University, Nanjing, China. Electronic address: septsoul@hotmail.com.
  • Li M; Department of Radiology, Changhai Hospital, Naval Medical University, Shanghai, China. Electronic address: limingmin421@sina.com.
  • Wang L; Department of Urology, Changhai Hospital, Naval Medical University, Shanghai, China. Electronic address: wanglinhui@smmu.edu.cn.
  • Mir MC; Department of Urology, Valencian Oncology Institute Foundation, FIVO, Valencia, Spain.
  • Carbonara U; Department of Urology, Aldo Moro University, Bari, Italy.
  • Pandolfo SD; Division of Urology, VCU Health System, Richmond, VA, USA.
  • Black PC; Department of Urologic Sciences, The University of British Columbia, Vancouver, British Columbia, Canada.
  • Paul AK; Division of Hematology, Oncology and Palliative Care, Department of Internal Medicine, VCU Massey Cancer Center, Virginia Commonwealth University, Richmond, VA, USA.
  • Di Lorenzo G; Oncology Unit, Andrea Tortora Hospital, ASL Salerno, Pagani, Italy; Vincenzo Tiberio Department of Medicine and Health Sciences, University of Molise, Campobasso, Italy.
  • Porpiglia F; Department of Urology, San Luigi Gonzaga Hospital, University of Turin, Orbassano, Italy.
  • Mari A; Department of Clinical and Experimental Medicine, University of Florence. Unit of Oncologic Minimally-Invasive Urology and Andrology, Careggi Hospital, Florence, Italy.
  • Necchi A; Genitourinary Medical Oncology, IRCCS San Raffaele Hospital and Scientific Institute, Milan, Italy.
  • Rouprêt M; Department of Urology, GRC n°5, Predictive Onco-Uro, AP-HP, Hôpital Pitié-Salpêtrière, Sorbonne University, Paris, France.
  • Psutka SP; Department of Urology, University of Washington, Seattle Cancer Care Alliance, Seattle, WA, USA.
  • Autorino R; Division of Urology, VCU Health System, Richmond, VA, USA.
Eur Urol ; 81(4): 414-425, 2022 Apr.
Article en En | MEDLINE | ID: mdl-35101302
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias Urológicas / Inhibidores de Puntos de Control Inmunológico Tipo de estudio: Guideline / Incidence_studies / Prognostic_studies / Systematic_reviews Límite: Female / Humans / Male Idioma: En Revista: Eur Urol Año: 2022 Tipo del documento: Article País de afiliación: China Pais de publicación: Suiza
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias Urológicas / Inhibidores de Puntos de Control Inmunológico Tipo de estudio: Guideline / Incidence_studies / Prognostic_studies / Systematic_reviews Límite: Female / Humans / Male Idioma: En Revista: Eur Urol Año: 2022 Tipo del documento: Article País de afiliación: China Pais de publicación: Suiza